PTX
data caveat$62M11mo
Prescient Therapeutics
Oncology
OmniCAR platform for T-cell therapy; PTX-100 PI3K inhibitor in haematologic cancers
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$9.7M
Dec 2025 4C
Runway
11moCAUTION
Based on Dec 2025 4C
Market Cap
$62M
Burn Rate
$2.6M/qtr
Dec 2025 4C
Shares Outstanding
1.1B
Pipeline Assets
3
Latest Insight(1)
24 Feb 2026Half YearAppendix 4D and Half Year Financial Report
Cash$9.7B·Burn$6.5B/q·OCF$-6.5B
3M Price
PTX.ASX$0.059-28.0% 3M
Low $0.050High $0.084
Pipeline Assets (3)
OmniCAR (AML)acute myeloid leukaemia
PreclinicalOmniCAR (HER2+)HER2+ solid tumours
PreclinicalPTX-100cutaneous T-cell lymphoma
Phase 2Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
R&D Tax Incentive
$4.3M received43.5% ATO refund
FY2026received
Auto-extracted from 4C (2025-12-31)
$4.30M
How the R&D Tax Incentive works
Australian biotechs with < $20M aggregated turnover can claim a 43.5% refundable tax offseton eligible R&D expenditure each financial year (Jul–Jun). This is paid as a cash refund by the ATO — not a tax deduction — making it non-dilutive capital that directly extends cash runway.
Companies register eligible R&D activities with AusIndustry during the year, then lodge their tax return after 30 June. Refunds typically arrive October–Decemberof the same calendar year. For a company spending $5M/year on R&D, this is a ~$2.2M annual cash inflow.
Disclaimer: Amounts shown as estimated or registeredare forward-looking estimates based on disclosed R&D expenditure and the 43.5% offset rate. Actual refunds may differ due to ATO assessments, eligibility rulings, or changes in R&D spend. This is not financial advice. Manually curated from 4C filings and company disclosures — verify independently.
Competitive Landscape
2 approved drugs626 competitor trialsPhase 2+ · Non-ASX
Acute Myeloid Leukaemia501 active trials
9 Ph468 Ph320 Ph2/3280 Ph2124 Ph1/PHASE2
Her2+ Solid Tumours82 active trials
1 Ph43 Ph2/329 Ph249 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
15 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Public Health Pract (Oxf)2026-06· HER2+
Oncol Lett2026-06· HER2+
Oncol Lett2026-05· HER2+
Catalysts (1)
SpeculativeremoveMed1 Jan 2028
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| PHASE2 data readout — A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCLopen_in_new Primary completion expected for NCT06854653. Indication: {CTCL} | data readout | Speculative | removeMed | 1 Jan 2028 |
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.
Clinical Trials(3)
1 activeClinicalTrials.gov ↗
Ph2RecruitingEnrollment stale · 390d
PTX-100
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
CTCL
RandomizedOpen Label18 Years+
Primary endpoint To determine the efficacy of PTX-100 as determined by ORR.
Announcements(5)
description
Half YearPSauto_awesome
Appendix 4D and Half Year Financial Report24 Feb 2026
expand_more1021KB
payments
Quarterly 4CPSauto_awesome
December 2025 Quarterly Update and Appendix 4C29 Jan 2026
expand_more276KB